Should off-pump CABG be abandoned? Joseph Sabik of the Cleveland Clinic, Cleveland, Ohio, suggests that while off-pump CABG should not be completely abandoned, it should no longer be the default option.
ALERT!
This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
Coronary disease
April 23, 2016
An editorial discussion of the impressive 10-year benefits of CABG for ischemic cardiomyopathy as found in the STICH trial.
April 3, 2016
In a propensity-matched analysis, Rosenblum and colleagues found that hybrid revascularization as compared with coronary artery bypass grafting with either single or bilateral internal mammary artery grafts was superior in terms of secondary short-term outcomes (e.g.
March 29, 2016
Joseph Sabik of the Cleveland Clinic, Cleveland, Ohio, considers whether the SYNTAX trial changed cardiology and cardiothoracic surgery practice in the United States.
March 23, 2016
Guidelines recommend that ICDs should not be implanted until after 90 days following revascularization in patients with an EF<35% and an MI. Studies have shown that no clinical benefit or detriment was derived by implantation prior to 90 days.
March 22, 2016
This retrospective study evaluated the relationship between the timing betweenLHC and CABG and its effect on renal function in a cohort of 2371 patients at a single center. Findings included:
March 14, 2016
The Hopkins group reviewed differential outcomes in close to 800 patients who had undergone bilateral IMA revascularization during CABG. The compared configurations included:
March 13, 2016
This Belgian study prospectively analyzed the predictors of long-term mortality in a group of 107 consecutive CABG patients with an LV EF < 35%. All patients underwent preoperative Cardiac MR to assess both LV and RV EF.
March 13, 2016
The authors reviewed the Medicare database to analyze the trends in CABG surgery within this population over a 12-year period. Trends in the Medicare population included the following:
March 11, 2016
The authors provide an excellent overview of the rationale for screening all patients with a new diagnosis of cardiomyopathy for coronary artery disease. This rationale includes the following: